Small Molecule Development & Manufacturting at Quotient Sciences

Accelerating Drug Product Optimization using Translational Pharmaceutics® - Campus Biotech, Geneva, Switzerland

Campus Biotech, Geneva, Switzerland | 19 September 2024
Overview

Drug product optimization is a critical development step that is common for most drugs that are progressing through today’s development pipelines to respond to suboptimal exposure profiles, to transition from an early development formulation to one suitable for chronic administration in patients, or as part of a life-cycle management strategy.

Traditional drug product optimization processes take 12-18 months to complete and place significant emphasis on the predictive power of laboratory and preclinical assessments. This approach is a non-optimal working model necessitated by the multiple disciplines required to develop, make and test new formulations in humans.

In this presentation, John McDermott will describe the application of Quotient Sciences’ Translational Pharmaceutics to re-engineer and streamline the drug product optimization process, using clinical data to improve decision-making and halve development timelines.

Learning Objectives:

  • Develop an understanding of Translational Pharmaceutics when applied to drug product optimization
  • Hear case studies on reformulation programs 
     

Date 19th September - Agenda

Arrival – 4.30pm
Seminar– 5-6pm
Drinks & Networking 6-8pm

 

 

*This is an in person event that will not be recorded. A virtual option to attend is not available.

**We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register now
Times

Agenda 
Arrival – 4.30pm   
Seminar– 5-6pm   
Drinks & Networking 6-8pm 
 

Location
Thur. September 19th, 2024 Campus Biotech
Room H8-01-C, Chem. des Mines 9,
Campus Biotech, Geneva, Switzerland

Meet our speaker:

In this presentation, John McDermott will describe the application of Quotient Sciences’ Translational Pharmaceutics to re-engineer and streamline the drug product optimization process, using clinical data to improve decision-making and halve development timelines. 

John McDermott

Vice President, Scientific Consulting

John McDermott is Vice President of Scientific Consulting at Quotient Sciences. John leads Quotient Sciences' global drug developm...

About John

More insight from our experts:

Read More
Drug Product, Integrated Programs, Dr. Asma Patel, Rare Diseases, Orphan Drugs Accelerated pathways and CMC challenges in rare disease drug development By: Dr. Asma Patel
Learn more
Thierry Van Nieuwenhove, Translational Pharmaceutics, Integrated Programs, Drug Product, Clinical Pharmacology Interview with Thierry Van Nieuwenhove: On Quotient Sciences' Growth and Role in Accelerating Drug Development By: Thierry Van Nieuwenhove
Learn more